Open AccessIs Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms?
Author(s) -
Sima L. Sharara,
Joe Amoah,
Zoi Dorothea Pana,
Patricia J. Simner,
Sara E. Cosgrove,
Pranita D. Tamma
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz1205
Subject(s) - medicine , proteus mirabilis , carbapenem , piperacillin/tazobactam , tazobactam , klebsiella pneumoniae , pyuria , intensive care unit , odds ratio , klebsiella oxytoca , piperacillin , confidence interval , urine , surgery , antibiotics , imipenem , microbiology and biotechnology , pseudomonas aeruginosa , antibiotic resistance , escherichia coli , biochemistry , chemistry , genetics , bacteria , gene , biology
Limited data exist regarding the efficacy of piperacillin-tazobactam (TZP) for the management of nonbacteremic pyelonephritis caused by extended-spectrum β-lactamase (ESBL)-producing organisms.